Table 2.
Demographics and frequency of diagnoses for the entire cohort, as well as by site
| Entire cohort | Dundee | Aberdeen | Glasgow | |
| n | 323 | 190 | 41 | 92 |
| Age (years) | 53.4 | 57 | 54 | 49.3 |
| % Female | 49.5% | 53% | 54% | 41% |
| BMI | 29.9 | 30.3 | 29.5 | 29.4 |
| Diagnosis | ||||
| PBC | 19 | 18 | 1 | 0 |
| AIH | 19 | 17 | 2 | 0 |
| HCV | 48 | 4 | 1* | 43* |
| HBV | 9 | 6* | 3* | |
| Haemochromatosis | 12 | 6 | 2 | 4 |
| Wilson’s disease | 0 | 0 | 0 | 0 |
| A1AT | 4 | 4 | 0 | 0 |
| NAFLD, no fibrosis | 78 | 60 | 8 | 10 |
| NAFLD with fibrosis | 37 | 21 | 8 | 8 |
| ARLD, no fibrosis | 21 | 16 | 2 | 3 |
| ARLD with fibrosis | 24 | 8 | 1 | 15 |
| Isolated elevated Alk Phos | 10 | 7 | 0 | 3 |
| Gilbert’s syndrome | 0 | 0 | 0 | 0 |
| DILI | 8 | 8 | 0 | 0 |
| Unclear | 34 | 21 | 10 | 3 |
*One case of HBV/HCV coinfected.
A1AT, alpha 1 antitrypsin; AIH, autoimmune hepatitis; Alk Phos, alkaline phosphatse; ARLD, alcohol-related liver disease; BMI, body mass index; DILI, drug-induced liver injury; HBV, hepatitis B virus infection; HCV, hepatitis C virus infection; NAFLD, non-alcoholic fatty liver disease; PBC, primary biliary cholangitis.